ATE296634T1 - (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen - Google Patents

(s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen

Info

Publication number
ATE296634T1
ATE296634T1 AT04013382T AT04013382T ATE296634T1 AT E296634 T1 ATE296634 T1 AT E296634T1 AT 04013382 T AT04013382 T AT 04013382T AT 04013382 T AT04013382 T AT 04013382T AT E296634 T1 ATE296634 T1 AT E296634T1
Authority
AT
Austria
Prior art keywords
reboxetine
fibromyalgia
treatment
somatoform disorders
somatoform
Prior art date
Application number
AT04013382T
Other languages
English (en)
Inventor
Saeeduddin Ahmed
Lars Birgerson
Pasquale Cetera
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Erik H F Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296634(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE296634T1 publication Critical patent/ATE296634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04013382T 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen ATE296634T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (1)

Publication Number Publication Date
ATE296634T1 true ATE296634T1 (de) 2005-06-15

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
AT04013381T ATE305788T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von inkontinenz
AT04013383T ATE304358T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von migränekopfschmerzen
AT05111704T ATE364386T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
AT04025513T ATE319453T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AT04013382T ATE296634T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AT04025514T ATE305307T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von migränekopfschmerzen
AT04013379T ATE292971T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von peripheren neuropathien
AT00941659T ATE320257T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung chronischer schmerzen
AT04023888T ATE305306T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von peripheren neuropathien

Family Applications Before (4)

Application Number Title Priority Date Filing Date
AT04013381T ATE305788T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von inkontinenz
AT04013383T ATE304358T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von migränekopfschmerzen
AT05111704T ATE364386T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
AT04025513T ATE319453T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen

Family Applications After (4)

Application Number Title Priority Date Filing Date
AT04025514T ATE305307T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von migränekopfschmerzen
AT04013379T ATE292971T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetin zur behandlung von peripheren neuropathien
AT00941659T ATE320257T1 (de) 1999-07-01 2000-06-22 (s,s)-reboxetine zur behandlung chronischer schmerzen
AT04023888T ATE305306T1 (de) 1999-07-01 2000-06-22 Reboxetin zur behandlung von peripheren neuropathien

Country Status (31)

Country Link
US (18) US6465458B1 (de)
EP (3) EP1196172B1 (de)
JP (3) JP2003503450A (de)
KR (5) KR20090087135A (de)
CN (5) CN1289090C (de)
AR (1) AR035158A1 (de)
AT (9) ATE305788T1 (de)
AU (2) AU771258B2 (de)
BR (1) BR0012136A (de)
CA (2) CA2375908C (de)
CL (3) CL2008002866A1 (de)
CO (1) CO5190662A1 (de)
CZ (1) CZ299847B6 (de)
DE (9) DE60022916T2 (de)
DK (4) DK1632234T3 (de)
EA (6) EA200801806A1 (de)
ES (9) ES2242175T3 (de)
GE (1) GEP20094798B (de)
HK (2) HK1049630A1 (de)
HU (1) HUP0201623A3 (de)
IL (3) IL147246A0 (de)
MX (1) MXPA02000562A (de)
MY (1) MY137348A (de)
NO (4) NO20016406L (de)
NZ (2) NZ533243A (de)
PE (1) PE20010684A1 (de)
PL (1) PL196996B1 (de)
PT (5) PT1196172E (de)
SK (5) SK286104B6 (de)
TW (9) TW200922594A (de)
WO (1) WO2001001973A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022916T2 (de) * 1999-07-01 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Reboxetin zur Behandlung von peripheren Neuropathien
RO121085B1 (ro) * 1999-12-01 2006-12-29 Ucb, S.A., Utilizarea levetiracetamului, în tratamentul bolilor sistemului nervos central
CN1418099A (zh) * 2000-04-21 2003-05-14 法玛西雅厄普约翰美国公司 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物
NZ531171A (en) 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
EP1333835A1 (de) * 2000-10-31 2003-08-13 Head Explorer A/S Anwendung von selektiven noradrenalin-reuptake-hemmern für die behandlung von spannungskopfschmerzen
EP1395253A2 (de) * 2000-11-15 2004-03-10 Eli Lilly And Company Behandlung von angstzuständen
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
ATE452642T1 (de) * 2001-06-19 2010-01-15 Norbert Mueller Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
CN1713900A (zh) * 2001-12-11 2005-12-28 伊莱利利公司 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
BR0311878A (pt) * 2002-06-17 2005-04-05 Pharmacia Italia Spa Sais farmacêuticos de reboxetina
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
WO2004016272A1 (en) * 2002-08-14 2004-02-26 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP1546123B1 (de) * 2002-08-23 2006-05-31 Eli Lilly And Company Benzylmorpholinderivate
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
US6846823B2 (en) * 2003-04-04 2005-01-25 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
BRPI0414343A (pt) * 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
EP1745029A1 (de) 2004-04-30 2007-01-24 Warner-Lambert Company LLC Substituierte morpholinverbindungen zur behandlung von erkrankungen des zentralen nervensystems
EP1763354A2 (de) * 2004-06-09 2007-03-21 Pfizer Limited Verwendung von reboxetin zur schmerzbehandlung
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
JP4785847B2 (ja) 2004-08-13 2011-10-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
EP1793829A1 (de) * 2004-10-01 2007-06-13 Neurocure Ltd. Verwendung von pharmazeutischen zusammensetzungen von lofepramin zur behandlung von adhd, cfs, fm und depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP3132792B1 (de) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Zusammensetzung und verfahren zur erhöhung der insulinempfindlichkeit
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2363123A1 (de) * 2006-06-28 2011-09-07 Chelsea Therapeutics, Inc. Pharmazeutische Zusammensetzungen enthaltend Droxidopa
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2480966T3 (es) 2007-03-09 2014-07-29 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
CA2686723A1 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
ES2434250T3 (es) * 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
MX2012000685A (es) * 2009-07-13 2012-02-28 Theravance Inc Compuesto de 3-fenoximetilpirrolidina.
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
MA37714A1 (fr) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Méthodes de traitement de la surcharge pondérale et de l'obésité
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (de) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
KR20220108122A (ko) * 2019-12-03 2022-08-02 액섬 테라퓨틱스, 인크. 신경계 장애 치료를 위한 레복세틴의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU642582B2 (en) 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
UA48219C2 (uk) 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ES2125696T3 (es) 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EP1007041A4 (de) 1997-04-11 2001-03-07 Lilly Co Eli Zusammensetzung zur behandlung von schmerzen
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
KR20010034758A (ko) 1998-04-09 2001-04-25 로렌스 티. 마이젠헬더 신경 장애의 신규 치료 방법
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
SI1075264T1 (en) 1998-05-08 2005-06-30 Pharmacia & Upjohn Company New drug combinations of reboxetine and pindolol
CN1331576A (zh) 1998-06-29 2002-01-16 药品应用协会有限公司 用于缓解疼痛的方法和经皮组合物
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
DE60022916T2 (de) 1999-07-01 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Reboxetin zur Behandlung von peripheren Neuropathien
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
NZ520975A (en) 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
DE60026627T2 (de) 2007-02-01
ES2242175T3 (es) 2005-11-01
PT1459751E (pt) 2005-11-30
ES2246488T3 (es) 2006-02-16
CN1660109A (zh) 2005-08-31
GEP20094798B (en) 2009-10-26
EA008381B1 (ru) 2007-04-27
EP2087892A2 (de) 2009-08-12
SK286864B6 (sk) 2009-06-05
ES2246485T3 (es) 2006-02-16
US20060142289A1 (en) 2006-06-29
CO5190662A1 (es) 2002-08-29
ATE305307T1 (de) 2005-10-15
AU2004202096A1 (en) 2004-06-10
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (de) 2002-04-17
US7338953B2 (en) 2008-03-04
SK286668B6 (sk) 2009-03-05
EA011094B1 (ru) 2008-12-30
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
US20020061910A1 (en) 2002-05-23
ES2239311T3 (es) 2005-09-16
ATE304358T1 (de) 2005-09-15
TWI245631B (en) 2005-12-21
CA2375908C (en) 2006-05-30
US6987107B2 (en) 2006-01-17
AU771258B2 (en) 2004-03-18
US7276503B2 (en) 2007-10-02
ATE364386T1 (de) 2007-07-15
EA005029B1 (ru) 2004-10-28
CZ299847B6 (cs) 2008-12-10
KR100935277B1 (ko) 2010-01-06
US20060135520A1 (en) 2006-06-22
US6465458B1 (en) 2002-10-15
TWI293250B (en) 2008-02-11
KR20060099544A (ko) 2006-09-19
ES2246487T3 (es) 2006-02-16
KR100704319B1 (ko) 2007-04-09
NO20091159L (no) 2002-02-19
CN1379672A (zh) 2002-11-13
DE60019473D1 (de) 2005-05-19
US20060128705A1 (en) 2006-06-15
DE60020613D1 (de) 2005-07-07
ATE305788T1 (de) 2005-10-15
WO2001001973A3 (en) 2002-01-17
US20060135521A1 (en) 2006-06-22
US20020107249A1 (en) 2002-08-08
TW200607511A (en) 2006-03-01
EA006652B1 (ru) 2006-02-24
US20090247528A1 (en) 2009-10-01
EA200400589A1 (ru) 2004-12-30
EA200501496A1 (ru) 2006-06-30
KR20020015363A (ko) 2002-02-27
WO2001001973A8 (en) 2001-05-17
KR20090087135A (ko) 2009-08-14
DE60019473T2 (de) 2006-02-23
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
PL196996B1 (pl) 2008-02-29
CN1660108A (zh) 2005-08-31
IL187512A0 (en) 2008-06-05
DE60022692D1 (de) 2005-10-20
CN1289090C (zh) 2006-12-13
US20060264436A1 (en) 2006-11-23
CL2008002868A1 (es) 2009-01-09
TW200607510A (en) 2006-03-01
KR100948757B1 (ko) 2010-03-23
DE60022917T2 (de) 2006-06-29
DK1459749T3 (da) 2006-01-09
SK19382001A3 (sk) 2002-07-02
AU2004202096B2 (en) 2005-10-20
US20080103145A1 (en) 2008-05-01
PT1196172E (pt) 2006-05-31
PL352252A1 (en) 2003-08-11
TW200407146A (en) 2004-05-16
CA2375908A1 (en) 2001-01-11
TWI294779B (en) 2008-03-21
TWI298254B (en) 2008-07-01
MY137348A (en) 2009-01-30
ATE320257T1 (de) 2006-04-15
CN1205935C (zh) 2005-06-15
PT1459750E (pt) 2005-08-31
US6642235B2 (en) 2003-11-04
US20080103147A1 (en) 2008-05-01
EA200801806A1 (ru) 2008-12-30
US20040147614A1 (en) 2004-07-29
EP2087892A3 (de) 2009-09-30
DE60023043T2 (de) 2006-06-14
DE60023043D1 (de) 2006-02-16
DE60035232T2 (de) 2008-02-14
EA200200111A1 (ru) 2002-06-27
NZ515885A (en) 2004-08-27
AR035158A1 (es) 2004-05-05
ES2258010T3 (es) 2006-08-16
ES2258251T3 (es) 2006-08-16
CA2643231A1 (en) 2001-01-11
CN1660110A (zh) 2005-08-31
ATE305306T1 (de) 2005-10-15
EP2090312A1 (de) 2009-08-19
SK286104B6 (sk) 2008-03-05
DK1196172T3 (da) 2006-06-19
HK1049630A1 (en) 2003-05-23
US20020128173A1 (en) 2002-09-12
PE20010684A1 (es) 2001-06-24
KR20050053799A (ko) 2005-06-08
NO20016406D0 (no) 2001-12-28
IL187513A0 (en) 2008-06-05
DE60035232D1 (de) 2007-07-26
CZ20014625A3 (cs) 2002-08-14
SK286669B6 (sk) 2009-03-05
NO20091168L (no) 2002-02-19
US7317011B2 (en) 2008-01-08
TW200920378A (en) 2009-05-16
DK1632234T3 (da) 2007-09-17
EA200801805A1 (ru) 2008-12-30
JP2006321815A (ja) 2006-11-30
US6703389B2 (en) 2004-03-09
JP2003503450A (ja) 2003-01-28
US7723334B2 (en) 2010-05-25
IL147246A0 (en) 2002-08-14
TW200607512A (en) 2006-03-01
HUP0201623A2 (en) 2002-09-28
ES2285645T3 (es) 2007-11-16
PT1632234E (pt) 2007-07-09
NZ533243A (en) 2005-12-23
DE60022692T2 (de) 2006-06-22
NO20091158L (no) 2002-02-19
DE60026704T2 (de) 2006-10-19
DE60020613T2 (de) 2006-03-16
TWI298255B (en) 2008-07-01
CN1660111A (zh) 2005-08-31
MXPA02000562A (es) 2002-07-02
KR20090087134A (ko) 2009-08-14
WO2001001973A2 (en) 2001-01-11
DE60022917D1 (de) 2006-02-09
CL2008002867A1 (es) 2009-01-09
US20080096890A1 (en) 2008-04-24
DE60022916T2 (de) 2006-07-06
DE60026627D1 (de) 2006-05-04
NO20016406L (no) 2002-02-19
TW200914027A (en) 2009-04-01
KR100717660B1 (ko) 2007-05-15
DE60022916D1 (de) 2006-02-09
US20030040464A1 (en) 2003-02-27
US20080103146A1 (en) 2008-05-01
ATE292971T1 (de) 2005-04-15
US6610690B2 (en) 2003-08-26
ES2247572T3 (es) 2006-03-01
DE60026704D1 (de) 2006-05-11
SK286667B6 (sk) 2009-03-05
EP1196172B1 (de) 2006-03-15
US7241762B2 (en) 2007-07-10
HK1076723A1 (en) 2006-01-27
AU5633700A (en) 2001-01-22
ATE319453T1 (de) 2006-03-15
JP2006143749A (ja) 2006-06-08
CL2008002866A1 (es) 2009-01-09
TW200607509A (en) 2006-03-01
BR0012136A (pt) 2002-06-11
DK1459750T3 (da) 2005-08-15
HUP0201623A3 (en) 2004-12-28

Similar Documents

Publication Publication Date Title
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE376994T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69735162D1 (de) L-carnosin enthaltende mittel zur behandlung des nierenversagens
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
TR200200278T2 (tr) Kalsilitik bileşimler
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATA159597A (de) Präparat zur behandlung von blutgerinnungsstörungen
DE29807046U1 (de) Vorrichtung zur abtragenden Behandlung von Hornhaut
ATA17797A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA157396A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1459750

Country of ref document: EP

REN Ceased due to non-payment of the annual fee